Live
FierceBiotechTakeda tears up Denali partnership, returning dementia asset amid restructuringFierceBiotechAI model designs new treatment candidate for opioid addiction that cuts cravings in ratsBioPharma DiveHims & Hers says limited data stolen in social engineering attackLonza NewsLonza Group AG stock: What investors should know about its biotech edge now - AD HOC NEWSBioPharma DiveUnder-the-skin Tepezza comparable to infused version in key study, Amgen saysEndpoints NewsProposed FDA budget sets Makary up to boost US biotechFierceBiotechWith Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engineFierceBiotechUS, UK regulators bolster medical device collaboration while lifting tariffsFierceBiotechZeto’s latest EEG device garners FDA 510(k) clearance for outpatient useFierceBiotechAnthropic acquires stealth AI startup Coefficient Bio in $400M deal: reportsBioWorldAppointments and advancements for April 6, 2026BioWorldFinancings for April 6, 2026
Endpoints News Mar 17, 2026

Rhythm’s Imcivree fails Phase 3 rare form obesity trial

Rhythm’s Imcivree fails Phase 3 rare form obesity trial

Original
Body unavailable. Use the original source.

Directory

59 All